DimerixASX:DXB +2.56%32 EBITDA Margin % is -1,026.55% as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Dimerix ranks worse than 72.49% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dimerix's EBITDA for the
six
months ended in Dec. 2025 was A$-21.73 Mil. Dimerix's Revenue for the
six
months ended in Dec. 2025 was A$2.12 Mil. Therefore, Dimerix's EBITDA margin for the quarter that ended in Dec. 2025 was -1,026.55%.
Dimerix (ASX:DXB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dimerix EBITDA Margin % Related Terms
Dimerix EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dimerix's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:DXB vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Dimerix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimerix EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dimerix's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dimerix's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimerix (ASX:DXB) has a EBITDA Margin % of -1,026.55% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #685 out of 945 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Dimerix's EBITDA Margin % too high?
Dimerix's current EBITDA Margin % is -1,026.55%. Based on the distribution chart, Dimerix ranks #685 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #685 out of 945 companies for EBITDA Margin %. This places Dimerix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dimerix and its competitors. Dimerix's current EBITDA Margin % is -1,026.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current EBITDA Margin % of -1,026.55%. The current EBITDA Margin % is -1,026.55%. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current EBITDA Margin % is -1,026.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score
Get the complete analysis for ASX:DXB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:DXB has been successfully added to your 
